Searching for keyword:"Cancer"

37,864 results
Record publications over time
Ironsift results are limited for unregistered users. Register or log in to see all records.

US Clinical Trial NCT03574194 – NIH – Jun 15, 2018

Methionine-Restricted Diet to Potentiate The Effects of Radiation Therapy

Radiation therapy (RT) is often given concurrently with systemic chemotherapy in order to sensitize the cancer cells to radiation and increase local and regional disease control. However, chemotherapy is often associated with significant toxicity an...
Full record

US Clinical Trial NCT00709462 – NIH – Jul 1, 2008

A Phase I, Open-Label, Dose-Escalation, Multidose Study of CDX-1307, a Mannose Receptor-Targeted hCG-β Vaccine, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX-1307-01)

Protocol CDX1307-01: CDX-1307 is an investigational drug that is being tested to see if it can stimulate the immune system (the cells and substances that protect the body from infection and foreign matter) of people with certain kinds of cancer. It...
Full record

US Clinical Trial NCT00861107 – NIH – Mar 12, 2009

Phase I/II Study of a Therapeutic Cancer Vacccine Created In-situ in Patients With Refractory or Metastatic Cancer

This is a Phase I/II clinical study to investigate the feasibility of creating a personalized anti-tumor vaccine within the body of patients with advanced cancers. The aim of the study is to evaluate the safety of administration and anti-tumor effec...
Full record

US Clinical Trial NCT02303353 – NIH – Nov 3, 2014

Data Base Project for Acquisition of Cancer Patient Data in Practices and Ambulant Therapy

No preview available.
Full record

US Clinical Trial NCT01234987 – NIH – Nov 3, 2010

Diagnosis of Cancer Using Breath Samples

No preview available.
Full record

US Clinical Trial NCT00379782 – NIH – Sep 20, 2006

To be eligible, patients must have Medicare parts A and B, not enrolled in a managed care plan, not enrolled in hospice, and if currently have cancer, it must be either breast, cervical, colorectal, lung, or prostate. Patients may be enrolled up to...
Full record

US Clinical Trial NCT02993900 – NIH – Nov 30, 2016

A Clinical Trial To Evaluate Image-Guided Gynecologic Brachytherapy In The MR Simulator Suite

The goal of this trial is to assess how magnetic resonance imaging (MRI) may be used to improve tumor and normal tissue volume delineation, reducing toxicity and recurrence in gynecologic brachytherapy. To analyze the correlation of T2 and diffusion...
Full record

US Clinical Trial NCT00291473 – NIH – Feb 10, 2006

Safety and Immunogenicity of Cholesterol-Bearing Hydrophobized Pullulan HER2 Protein 146 (CHP-HER2) and NY-ESO-1 Protein (CHP-NY-ESO-1) in Combination With OK-432 in HER2- and/or NY-ESO-1-Expressing Cancers

No preview available.
Full record

US Clinical Trial NCT03634501 – NIH – Aug 3, 2018

Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killer(NK)Cells

No preview available.
Full record

US Clinical Trial NCT00379743 – NIH – Sep 20, 2006

Cancer Prevention and Treatment Among African American Older Adults: Screening Trial

Among African American seniors, compared to a less intensive intervention (general information and educational materials), does the addition of facilitation services delivered by a health coordinator result in a greater improvement in adherence to c...
Full record

US Clinical Trial NCT00439608 – NIH – Feb 22, 2007

Cetuximab, Paclitaxel, Carboplatin and Radiation for Esophageal, Gastroesophageal Junction and Gastric Cancer BMS#CA225091

The primary objective of this phase II trial is to estimate the rate of complete pathologic response as determined by surgical resection or post treatment endoscopy (for patients not undergoing resection) for the treatment regimen being tested. With...
Full record
Register to view full records and advanced analytics.

US Clinical Trial NCT02333279 – NIH – Dec 18, 2014

Cancer Development In Organ Transplant Recipients

This cohort analyses will focus on incident and recurrent cases of development of non-skin cancer over time. We will consider time to first formation of non-skin solid cancer after solid organ transplantation as well as the cumulative number of non-...
Full record

US Clinical Trial NCT00215995 – NIH – Sep 19, 2005

A Phase II Study of Cisplatin and Irinotecan Induction Chemotherapy, Followed by ZD 1839 (IRESSA) in Adult Patients With Surgically Unresectable and/or Metastatic Esophageal or Gastric Carcinomas

This is an open-label, non-randomized, multicenter Phase II study designed to evaluate tumor response rates in patients with surgically unresectable and/or metastatic esophageal, esophagogastric, and gastric adenocarcinoma or squamous carcinoma. Stu...
Full record

US Clinical Trial NCT00539968 – NIH – Oct 4, 2007

An Open-Label, Two-Part Study to Determine the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel

No preview available.
Full record

US Clinical Trial NCT02946671 – NIH – Oct 5, 2016

Phase I Study of Pre-operative Combination Therapy With Mogamulizumab (Anti-CCR4) and Nivolumab (Anti-PD-1) Against Solid Cancer Patients

No preview available.
Full record

US Clinical Trial NCT03790423 – NIH – Dec 20, 2018

Phase I: PET Imaging of Tissue Factor (TF) Expression in Patients With Primary and Metastastic Cancer Using 18F-ASIS.

The primary objective of the trial is to test the new radio tracer 18F-ASIS for PET imaging of tissue factor (TF) expression. The tracer has the potential of identifying tumors with high levels of TF expression, which is expected to correlate with t...
Full record

US Clinical Trial NCT00376909 – NIH – Sep 13, 2006

New York Prevention Care Manager Project

OBJECTIVES: - Determine whether telephone support for patients, provided through a Prevention Care Manager (PCM), can increase breast, cervical, and colorectal cancer screening rates among minority and low-income women. - Measure the amount of PCM...
Full record

US Clinical Trial NCT00061308 – NIH – May 23, 2003

An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer

No preview available.
Full record

US Clinical Trial NCT00477646 – NIH – May 23, 2007

New York Prevention Care Manager Project / Medicaid Managed Care Organization Version

OBJECTIVES: Primary - Develop and evaluate an enhanced telephone support intervention (Prevention Care Manager [PCM]) to promote colorectal, cervical, and breast cancer screening more widely among women enrolled in a Medicaid Managed Care Organiza...
Full record

US Clinical Trial NCT00579514 – NIH – Dec 20, 2007

Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients

To establish significant correlations between genetic polymorphisms and cancer, a largescale, systematic comparison of genetic alterations utilizing a case-control methodology is proposed. To date, such studies have been limited due to the large num...
Full record

US Clinical Trial NCT00899626 – NIH – May 9, 2009

Novel Colon Cancer Markers in Gastrointestinal Tissue and Biofluids

OBJECTIVES: - Identify new potential biomarkers of increased gastrointestinal cancer risk using tissue and biofluid samples from patients and healthy volunteers undergoing colonoscopy, endoscopy, or surgery. - Develop new screening strategies base...
Full record
Register to view full records and disable ads.

US Clinical Trial NCT01953159 – NIH – Sep 25, 2013

Validation of a Polygenic Neurotoxicity Risk Score in Patients With Unusually Severe Paclitaxel-Induced Neuropathy

No preview available.
Full record

US Clinical Trial NCT01214629 – NIH – Oct 1, 2010

A Phase I Study of LY2523355 in Patients With Advanced Cancer

This study is a multi-center, non-randomized, open label, dose-escalation, Phase 1 study of intravenous LY2523355 in participants with advanced and/or metastatic cancer (including Non-Hodgkin's Lymphoma) for whom no treatment of higher priority exis...
Full record

US Clinical Trial NCT02785887 – NIH – Mar 26, 2014

Impact of Geriatrician-implemented Interventions on Chemotherapy Delivery in Vulnerable Elderly Patients With Early or Metastatic Solid Malignancies: the GIVE Trial

This randomized parallel group trial is designed to evaluate the impact of implementing geriatrician-prescribed interventions, on the ability to deliver adequate chemotherapy treatment, as measured by RDI of at least 85%, in a cohort of vulnerable [...
Full record

US Clinical Trial NCT00588640 – NIH – Dec 22, 2007

A Phase I/II Study of D-Methadone in Patients With Chronic Pain

No preview available.
Full record

US Clinical Trial NCT00896935 – NIH – May 9, 2009

Arizona Cancer Center Biospecimen Repository

OBJECTIVES: - Provide cancer investigators access to a wide variety of tissues and biospecimens for translational studies in cancer. - Collect and preserve tissue from the primary organ site (uninvolved and involved with cancer), from the metastas...
Full record

US Clinical Trial NCT01223924 – NIH – Oct 9, 2010

Randomized ,Placebo-controlled,Single-dose Escalation Trial of M2ES in Healthy Volunteer

Randomized double-blinded placebo-controlled,single-dose escalation trial in health volunteer,to determine the safety and the max tolerate dose in health volunteer.
Full record

US Clinical Trial NCT00955773 – NIH – Aug 6, 2009

An Open-Label, Dose-Escalation, Phase IB II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor GSK1120212 in Combination With Oral Everolimus in Subjects With Solid Tumors

MEK112110 is a dose-escalation, open-label study to determine the recommended dose and regimen for the orally administered MEK inhibitor GSK1120212 dosed in combination with everolimus in subjects with solid tumors. This will be accomplished using a...
Full record

US Clinical Trial NCT01311388 – NIH – Mar 6, 2011

Construction of the "Patient-Centered"Molecular Pathology Diagnostic Center

This research is going to discuss the biomarker expression of common malignant neoplasm (tumor)among Taiwanese, such as large intestine rectal cancer, breast cancer, prostate gland cancer, lung cancer, oral cancer, gastric cancer, liver cancer, cerv...
Full record

US Clinical Trial NCT00791609 – NIH – Nov 13, 2008

Evaluation the Feasibility of the FOSTI Device Accurately and in a Real Time Way to Differentiate Malignant From Benign Tissue (Performed ex Vivo) in Cancer Surgery

Characterization of the optical fiber sensor's interaction with the tissue. Creating a database of tissue lesions and their 'optical signature' (lesion classifier). Optimization of the FOSTI device by minimizing the false-positive and false-negati...
Full record

US Clinical Trial NCT03934827 – NIH – Apr 15, 2019

A First in Human, Phase 1 Safety Study in Two Parts to Determine the Safety, Tolerability and Anti-cancer Immune-modulatory Effects of MRx0518 in Patients With Solid Tumour Awaiting Surgical Removal of the Tumour.

This is a first in human, single centre study in two parts, which aims to determine the safety and tolerability of the novel biotherapeutic compound, MRx0518, to examine its use as an anti-cancer and immune system modulating agent in patients with a...
Full record
Register to view full records and use our APIs.

US Clinical Trial NCT00408070 – NIH – Dec 5, 2006

Phase 2 Study of Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma

The aim of this study is to determine if the addition of bevacizumab to a regimen of carboplatin/paclitaxel increases the time to disease recurrence (longer remission for patients) in women that have Stage III suboptimally reduced or Stage IV ovaria...
Full record

US Clinical Trial NCT01375699 – NIH – Jun 15, 2011

Randomized Open-label Phase 1b Study of Doxorubicin-based Chemotherapy Regimens, With and Without Sildenafil, With Exploratory Analysis of Intermediate Cardiac Markers

Definitive study of sildenafil enhancement of anthracycline anticancer effects and cardioprotection would require a randomized, placebo-controlled trial involving large numbers of patients and many years of follow-up. It is appropriate to demonstrat...
Full record

US Clinical Trial NCT02000739 – NIH – Nov 6, 2013

Phase II GENIUS Trial of GENetically-Informed Therapies for Patients With previoUSly Treated Refractory Metastatic Cancer

Treatment with a personalized targeted therapy plan based on cancer genetics will improve time to disease progression (TTP) compared to standard therapies. By comparing A) a patient's TTP on targeted therapy vs. B) their TTP on their most recent pr...
Full record

US Clinical Trial NCT03199586 – NIH – Jun 23, 2017

First-in-Human, Dose Finding, Open Label Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma)

No preview available.
Full record

US Clinical Trial NCT00523432 – NIH – Aug 29, 2007

A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies

No preview available.
Full record

US Clinical Trial NCT00268918 – NIH – Dec 21, 2005

A Phase I Trial of Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Recurrent or Refractory Gynecological Cancer Patients

- Patients will come to the clinic once a week to receive study treatment. To help reduce the chance of an allergic reaction patients will take Decadron tablets orally the night before, the morning of and the evening of receiving chemotherapy. - Th...
Full record

US Clinical Trial NCT02583815 – NIH – Oct 20, 2015

Feasibility of Activity Monitoring in Patients With Cancer: Physical Activity Monitoring in Cancer Patients (PAMCap)

Study will be conducted for 12 weeks (+/-14 days) of monitoring. BASELINE ASSESSMENTS Baseline assessment should be performed within 14 days of Week 1. 1. Signed informed consent; 2. ECOG Performance Status per treating physician (chart abstracti...
Full record

US Clinical Trial NCT01822444 – NIH – Feb 25, 2013

Exploratory Phase II Clinical Trial Comprising Biomarker Analysis of Oxaliplatin Plus Fluorouracil/Leucovorin (FOLFOX) in Combination With Bevacizumab (Bvz) in First Line Treatment of Metastatic Colorectal Cancer (CRC) Expressing Mutant K-ras - AC-ANGIOPREDICT

Study Design: Type of Study: Exploratory, translational, multicenter and multinational Phase II study. Patient Population:All patients from the intent-to-treat population with aCRC or mCRC, (incurable with any conventional multimodality approach)...
Full record

US Clinical Trial NCT03852030 – NIH – Dec 12, 2018

Mind-Body Health in Uro-Oncology: A Randomized Controlled Trial

Participant accrual will occur at NorthShore University HealthSystem's John and Carol Walter Center for Urological Health. During or prior to an office visit, a potential subject and possibly his/her spouse will speak with the physician or research...
Full record

US Clinical Trial NCT03623464 – NIH – Apr 24, 2017

Randomized Clinical Trial of FitBit and Mobile Apps Versus Usual Care to Improve Post-Operative Outcomes After GI Cancer Surgery

Patients will be randomized to 1) standard of care or 2) to use our mobile app with standard care. The mobile app will collect information on patients' daily physical activity patterns and health status data for clinicians using smartphone mobile te...
Full record
Register to view full records and receive email notifications.

US Clinical Trial NCT00120939 – NIH – Jul 12, 2005

Phase I Trial of Motexafin Gadolinium (MGd) and Docetaxel Chemotherapy in the Treatment of Advanced Solid Tumors

No preview available.
Full record

US Clinical Trial NCT00581815 – NIH – Dec 20, 2007

Spectroscopy With Surface Coils and Decoupling

The investigators propose to use 1H spectroscopy or 1H decoupled 31P NMR spectroscopy to obtain biochemical information about tumor metabolism in patients, both before and after antineoplastic therapy. In healthy volunteers, normal tissue metabolism...
Full record

US Clinical Trial NCT03787056 – NIH – Oct 26, 2018

Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients

No preview available.
Full record

US Clinical Trial NCT02552121 – NIH – Sep 14, 2015

Dose-escalating and Cohort Expansion Safety Trial of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax®-TF-ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor

The study is conducted in two parts. In the Dose Escalation portion of the trial, subjects are enrolled into cohorts at increasing dose levels of tisotumab vedotin (HuMax-TF-ADC) in 28 day treatment cycles. The Cohort Expansion portion of the trial...
Full record

US Clinical Trial NCT03301493 – NIH – Sep 22, 2017

The Use of Genomic Testing and the Resulting Medical Decisions According to Target Identification

In the situation of enormous possible beneficial options for patients, health care systems, researchers and companies and the simultaneously present high number of uncertainties, the establishment of an independent registry for patients undergoing a...
Full record

US Clinical Trial NCT03604653 – NIH – Jul 12, 2018

Trial of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Primary Peritoneal Cancers and Secondary Peritoneal Cancers From Stomach, Colorectal, Appendiceal, and/or Gynecological Origins

Peritoneal carcinomatosis can be caused by primary peritoneal cancers and secondary peritoneal spread from stomach, colorectal, appendiceal, and/or gynecological cancers. Combined presentation of patients with peritoneal carcinomatosis make up about...
Full record

US Clinical Trial NCT01012362 – NIH – Nov 12, 2009

Phase I Study of Pazopanib and Ixabepilone in Patients With Solid Tumors

Treatment with ixabepilone will be given at an assigned dose as a 3 hour intravenous infusion on day 1 of a 21 day cycle. Treatment with pazopanib will be given at an assigned dose by mouth once a day, beginning on day 1 and continuing daily. Diseas...
Full record

US Clinical Trial NCT00587964 – NIH – Dec 26, 2007

Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases

This is a phase II trial in patients with 1-2 brain metastases treated with surgical resection followed by stereotactic radiosurgery boost. Following surgical resection, patients would receive a stereotactic radiosurgery boost to the surgical bed, 2...
Full record

US Clinical Trial NCT01684098 – NIH – Sep 9, 2012

A Phase II Clinical Study to Evaluate the Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor

This Phase II, limited institution, open-label, single-arm, baseline-controlled study is designed to obtain data on the percentage of patients with recurrent or metastatic cancer from a solid tumor (including, but not limited to, breast, lung, mesot...
Full record